DYNAVAX TECHNOLOGIES CORPORATION
Toll-like Receptor (TLR) agonist therapeutics and vaccines that stimulate innate and adaptive immune responses
- Sector
- Biotech
- Headquarters
- BERKELEY, CA
- Latest Form D
- $181K, May 2010
- Total capital
- $29.4M
- Federal grants
- $2M
- 3 awards · 2016–2017
- Rank in peer group#28 of 326
- Private capital raised
- $20.2M
- 2 Form D · last May 2010
- 197 months since last filing
- Federal contracts
- $7.1M
- 2 awards · Health and Human S, Justice
- Rank in Biotech#69 of 4373
- Granted patents
- 28
- 12 pending · first 2015
- Rank in peer group#4 of 326
Capital timeline
Latest events
- Federal contractJustice · Mckesson Controlled 9-5-25$364
- Federal grantHealth and Human S · Phase II · Developing small molecule inhibitors of TLR8 for treatment of rheumatoid arthritis$423K
- Federal grantHealth and Human S · Phase II · Developing small molecule inhibitors of TLR for treatment of rheumatoid arthritis$1M
- Federal grantHealth and Human S · Phase II · Developing small molecule inhibitors of TLR8 for treatment of rheumatoid arthritis$589K
- Private capital raisedForm D · SEC · 2nd filing$181K
- Private capital raisedForm D · SEC · 1st filing$20.1M
- Federal contractHealth and Human S · Biomedical (basic)$7.1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
15months
from DYNAVAX TECHNOLOGIES CORPORATION’s first federal award to its first private round.
- First federal award · Sep 2008
- Health and Human S · $7.1M
- First Form D · Jan 2010
- $20.1M · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grants#28 · top 9%
- Granted patents#4 · top 1%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Arnold S. Oronsky, Ph.D.DirectorNamed in SEC Form D filings
- David M. Lawrence, M.D.DirectorNamed in SEC Form D filings
- Denise M. Gilbert, Ph.D.DirectorNamed in SEC Form D filings
- Dennis R. Carson, M.D.DirectorNamed in SEC Form D filings
- Dino Dina, M.D.Executive Officer, DirectorNamed in SEC Form D filings
- Francis R. Cano, Ph.D.DirectorNamed in SEC Form D filings
Show all 14 people
- Jennifer S. LewExecutive OfficerNamed in SEC Form D filings
- Mark M. KesselDirectorNamed in SEC Form D filings
- Michael S. OstrachExecutive OfficerNamed in SEC Form D filings
- Nancy L. BucDirectorNamed in SEC Form D filings
- Peggy V. PhilipsDirectorNamed in SEC Form D filings
- Robert L. Coffman, Ph.D.Executive OfficerNamed in SEC Form D filings
- Stanley A. Plotkin, M.D.DirectorNamed in SEC Form D filings
- Zbigniew L. Janowicz, Ph.D.Executive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 28 granted of 40- PendingImmunogenic Compositions Against The Omicron Variant Of Severe Acute Respitory Syndrome Coronavirus 2 (SARS-COV-2)USPTOApplication 19118726
- GrantedProduction Of Vaccines Comprising Inactivated SARS-COV-2 Viral ParticlesUSPTOUS 12,605,442
- GrantedShingles Vaccines Comprising A TLR9 AgonistUSPTOUS 12,569,553
Show all 40 patent records
- Immunogenic Compositions Against The Omicron Variant Of Severe Acute Respitory Syndrome Coronavirus 2 (SARS-COV-2)May 7, 2026 · Application 19118726Pending
- Production Of Vaccines Comprising Inactivated SARS-COV-2 Viral ParticlesApr 21, 2026 · US 12,605,442Granted
- Shingles Vaccines Comprising A TLR9 AgonistMar 10, 2026 · US 12,569,553Granted
- Toll-like Receptor Antagonist Compounds And Methods Of UseAug 5, 2025 · US 12,378,255Granted
- IMMUNOGENIC COMPOSITIONS COMPRISING A RECOMBINANT NEURAMINIDASE AND CpG OLIGONUCLEOTIDE ADJUVANT, AND USES THEREOFMay 22, 2025 · Application 18838947Pending
- Immunogenicity Of A Cpg-adjuvanted Herpes Zoster VaccineMay 22, 2025 · Application 18723407Pending
- IMMUNOGENIC COMPOSITION AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)May 13, 2025 · US 12,296,002Granted
- Alkyl Chain Modified Imidazoquinoline TLR7/8 Agonist Compounds And Uses ThereofNov 7, 2024 · Application 18629809Pending
- Immunogenic Compositions And Methods For Immunization Against Variants Of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)Jun 20, 2024 · Application 18592811Pending
- Alkyl Chain Modified Imidazoquinoline TLR7/8 Agonist Compounds And Uses ThereofMay 14, 2024 · US 11,981,670Granted
- Method For Quantifying Cpg-containing Oligonucleotides In Compositions Comprising AlumJan 25, 2024 · Application 18267083Pending
- Toll-like Receptor Antagonist Compounds And Methods Of UseNov 28, 2023 · US 11,827,641Granted
- Coronavirus Vaccines Comprising A TLR9 AgonistJul 13, 2023 · Application 17908221Pending
- CpG-ADJUVANTED SARS-CoV-2 VIRUS VACCINEJun 27, 2023 · US 11,684,669Granted
- Toll-like Receptor Antagonist Compounds And Methods Of UseJun 28, 2022 · US 11,370,794Granted
- Alkyl Chain Modified Imidazoquinoline TLR7/8 Agonist Compounds And Uses ThereofSep 21, 2021 · US 11,124,510Granted
- Combination Of A PD-1 Antagonist And Cpg-c Type Oligonucleotide For Treating CancerAug 25, 2020 · US 10,751,412Granted
- Cleavable Conjugates Of TLR7/8 Agonist Compounds, Methods For Preparation, And Uses ThereofJul 28, 2020 · US 10,722,591Granted
- Alkyl Chain Modified Imidazoquinoline TLR7/8 Agonist Compounds And Uses ThereofApr 14, 2020 · US 10,618,896Granted
- Branched Chimeric Compounds, And Methods Of Use ThereofFeb 4, 2020 · US 10,548,975Granted
- Administration Of Polynucleotide Toll-like Receptor 9 Agonists For Treating CancerAug 6, 2019 · US 10,369,168Granted
- Linear Chimeric Compounds And Methods Of Use ThereofJul 16, 2019 · US 10,350,290Granted
- Methods And Compositions For Eliciting An Immune Response Against Hepatitis B VirusJun 11, 2019 · US 10,314,907Granted
- Immunostimulatory Sequence Oligonucleotides And Methods Of Using The SameFeb 5, 2019 · US 10,196,643Granted
- Intrapulmonary Administration Of Polynucleotide Toll-like Receptor 9 Agonists For Treating Cancer Of The LungOct 30, 2018 · US 10,111,899Granted
- Combination Of An ANTI-IL-10 Antibody And A Cpg-c Type Oligonucleotide For Treating CancerJun 14, 2018 · Application 15577377Pending
- Intrapulmonary Administration Of Polynucleotide Toll-like Receptor 9 Agonists For Treating Cancer Of The LungJun 12, 2018 · US 9,993,495Granted
- Branched And Linear Chimeric Compounds, Polynucleotides, Uses And Methods For Preparation ThereofApr 24, 2018 · US 9,950,064Granted
- Methods And Compositions For Eliciting An Immune Response Against Hepatitis B VirusFeb 6, 2018 · US 9,884,110Granted
- Human Toll-like Receptor Inhibitors And Methods Of Use ThereofJan 16, 2018 · US 9,868,955Granted
- Intratumoral Administration Of Particles Containing A Toll-like Receptor 9 Agonist And A Tumor Antigen For Treating CancerNov 16, 2017 · Application 15488353Pending
- Methods And Compositions For Inhibition Of Immune Responses And AutoimmunityOct 25, 2016 · US 9,476,053Granted
- Immunostimulatory Sequence Oligonucleotides And Methods Of Using The SameAug 23, 2016 · US 9,422,564Granted
- Methods Of Treatment Using TLR7 And/or TLR9 InhibitorsMay 24, 2016 · US 9,347,064Granted
- Long Term Disease Modification Using Immunostimulatory OligonucleotidesMay 10, 2016 · US 9,333,254Granted
- TLR8 Transgenic AnimalsJan 7, 2016 · Application 14694919Pending
- Human Toll-like Receptor Inhibitors And Methods Of Use ThereofJan 5, 2016 · US 9,228,184Granted
- Chimeric Immunomodulatory Compounds And Methods Of Using The Same-ivOct 22, 2015 · Application 14693727Pending
- Chimeric Immunomodulatory Compounds And Methods Of Using The Same-ivMay 12, 2015 · US 9,028,845Granted
- Methods And Compositions For Inhibition Of Innate Immune Responses And AutoimmunityFeb 19, 2015 · Application 14312533Pending
Related companies, and why
- DISCOVERX CORPSimilar federal contract value in Biotech · $7.6M in contracts
- PROSCI, INC.Similar federal contract value in Biotech · $7.5M in contracts
- Inhibikase Therapeutics, Inc.Similar federal contract value in Biotech · $7.1M in contracts
- MEDIGEN, INC.Similar federal contract value in Biotech · $7M in contracts
- REJUVENATE BIO INCSimilar federal contract value in Biotech · $6.3M in contracts
- BCN BIOSCIENCES LLCSimilar federal contract value in Biotech · $6.2M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .